# Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

> **NCT05565807** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhejiang ACEA Pharmaceutical Co. Ltd.** · enrollment: 84 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** STI-6129

## Key facts

- **NCT ID:** NCT05565807
- **Lead sponsor:** Zhejiang ACEA Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-09
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-02-19
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05565807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05565807, "Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05565807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*